GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (OTCPK:NICXF) » Definitions » 3-Year EPS without NRI Growth Rate

Nicox (NICXF) 3-Year EPS without NRI Growth Rate : 15.60% (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Nicox 3-Year EPS without NRI Growth Rate?

Nicox's EPS without NRI for the six months ended in Jun. 2023 was $-0.19.

During the past 3 years, the average EPS without NRI Growth Rate was 15.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was -0.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was 8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Nicox was 50.60% per year. The lowest was -48.10% per year. And the median was 7.70% per year.


Competitive Comparison of Nicox's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Nicox's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nicox's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Nicox's 3-Year EPS without NRI Growth Rate falls into.



Nicox 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Nicox  (OTCPK:NICXF) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Nicox 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Nicox's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Nicox (NICXF) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (OTCPK:NICXF) » Definitions » 3-Year EPS without NRI Growth Rate
Traded in Other Exchanges
Address
2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (NICXF) Headlines